Drug updated on 11/14/2023
|Capsule (oral: 100 mg, 200 mg)
|Ongoing and Completed Studies
- For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
- For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation.
- For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that are metastatic or where surgical resection is likely to result in severe morbidity.
- For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have progressed following treatment or have no satisfactory alternative therapy.
Product Monograph / Prescribing Information
|Rozlytrek (entrectinib) Prescribing Information.
|Genentech, South San Francisco, CA
Systematic Reviews / Meta-Analyses
|Clinical, pharmacoeconomic, ethics and stakeholder input combined report.
|Final clinical guidance report: entrectinib (Rozlytrek) - ROS1- positive non-small cell lung cancer.
|Entrectinib for treating NTRK fusion-positive solid tumours.
|Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
|Journal of Comparative Effectiveness Research
|Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy.